Receptors Regulating Gastrointestinal Motility
The key receptors regulating gut motility include 5-HT4 (serotonin), dopamine D2, motilin, muscarinic cholinergic, and nicotinic acetylcholine receptors, with 5-HT4 agonists being the most therapeutically relevant for prokinetic effects.
Primary Receptor Systems
Serotonergic (5-HT) Receptors
The serotonergic system represents the most clinically important pathway for modulating GI motility 1, 2:
5-HT4 receptors: These are the primary prokinetic targets. Prucalopride, a selective 5-HT4 agonist, enhances acetylcholine release in prokinetic pathways without the cardiac risks of earlier agents 1, 3. The mechanism works by strengthening natural reflexes rather than directly stimulating them 4.
5-HT3 receptors: Mediate signaling to the CNS and fast neurotransmission within the enteric nervous system. 5-HT3 antagonists (like ondansetron) control nausea/vomiting but tend to be constipating 1, 4.
5-HT1A receptors: Buspirone acts here and may improve early satiety, postprandial fullness, and bloating, though evidence is limited 1.
Dopamine D2 Receptors
Metoclopramide and domperidone are D2 antagonists that stimulate gastric emptying and small intestinal transit 1, 3. However, metoclopramide carries an FDA black box warning for tardive dyskinesia, and domperidone requires careful QTc monitoring due to cardiac risks 1, 3.
Motilin Receptors
Erythromycin acts as a motilin agonist and is particularly useful when migrating motor complexes are absent or impaired 1, 3. The effect is purely prokinetic (not antibiotic-related), but tachyphylaxis develops with continuous use, necessitating drug holidays 1, 3.
Cholinergic Receptors
- Muscarinic receptors: Mediate parasympathetic excitatory control over gastric and intestinal motility 5.
- Nicotinic acetylcholine receptors: Presynaptic nAChRs on cholinergic terminals facilitate ACh release, creating a positive feedback mechanism crucial for reliable neurotransmission 6.
Neurokinin-1 Receptors
Aprepitant, a neurokinin-1 antagonist, provides antiemetic effects without affecting gastric motor function 1.
Clinical Application Algorithm
For gastroparesis management 1:
- First-line: Metoclopramide (D2 antagonist) - despite risks, it has conditional recommendation with low-quality evidence
- Second-line: Erythromycin (motilin agonist) at low doses (40-150 mg) to minimize side effects
- Consider: Prucalopride (5-HT4 agonist), especially in idiopathic gastroparesis, though not first-line
- Domperidone: Reserved for patients with metoclopramide-induced neurologic effects or Parkinson's disease
For severe intestinal dysmotility 3:
- Octreotide (somatostatin analogue) may be dramatically beneficial, especially in systemic sclerosis when other treatments fail
- Parasympathomimetics (pyridostigmine) can help refractory constipation but carry cardiovascular risks
Critical Caveats
Cardiac safety: Earlier 5-HT4 agonists (cisapride, tegaserod) were withdrawn due to fatal arrhythmias. Prucalopride avoids this by not affecting cardiac potassium channels 3.
Tachyphylaxis: Erythromycin loses efficacy with continuous use; implement drug holidays (e.g., 3 weeks on, 1 week off) 1, 3.
Movement disorders: Metoclopramide's tardive dyskinesia risk is low but irreversible; assess at 4-8 weeks and monitor throughout treatment 1.
Antibiotic resistance: Long-term erythromycin/azithromycin use poses resistance concerns 1.
The evidence consistently shows that 5-HT4 agonists offer the best balance of efficacy and safety for prokinetic therapy, while D2 antagonists remain useful despite significant adverse effect profiles 1, 2.